Experience with a dual ART regimen in an elderly female patient with HIV infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents the successful experience with a dual (lopinavir/ritonavir + lamivudine) ART regimen in a 60-year-old patient with newly diagnosed HIV infection in the presence of polyvalent allergy and multiple comorbidities. This 4-year regimen has shown good tolerance, therapeutic remission of HIV infection, and HIV suppression. Immune system functions were restored. Taking into account the increase in the number of patients receiving ART, including the elderly with various comorbidities, it has been justified to incorporate simplified dual ART regimens in the protocols and to introduce them into clinical practice for certain groups of HIV-infected patients.

Full Text

Restricted Access

About the authors

Nataliya V. Matievskaya

Grodno State Medical University

Email: natamati@mail.ru
MD, Heard, Department of Infectious Diseases

Oksana V. Dolinskaya

Grodno State Medical University

Email: lilaturangova@gmail.com
Assistant, Department of Infectious Diseases

References

  1. Рассохин В.В., Бузунова С.А., Врацких Т.В., Пантелеева О.В., Торопов С.Э., Тотрова З.М., Голубкин А.А., Орлов Г.М., Беляков Н.А..Проблема старения и инвалидизации ВИЧ-инфицированных пациентов. ВИЧ-инфекция и иммуносупрессии 2015; 7(1): 7-15. doi.org/10.22328/2077-9828-2015-7-1-7-15
  2. Эпидситуация по ВИЧ-инфекции в Республике Беларусь по состоянию на 01.04.2021. http://cgeud.by/2021/04/14 [Epidsituation on HIV infection in the Republic of Belarus as of 01.04.2021]. (In Russ.). http://cgeud.by/2021/04/14
  3. Матиевская Н.В., Кашевник Т.И., Кратков О.В. ВИЧ-инфекция у пациентов пожилого возраста: клинические случаи. Актуальна инфектолопя 2020; 8(1): 45-9. doi: 10.22141/2312-413x.8.1.2020.196171
  4. Беляева В.В., Козырина Н.В., Куимова У.А., Голиусова М.Д., Ефремова О.С. Профилактика передачи ВИЧвдискордантных парах: информированность, осознание риска, поведение. Инфекционные болезни 2021; 10(1): 46-51. doi: 10.33029/2305-3496-2021-10-1-46-51
  5. World Health Organization (WHO) HIV/AID Ssection].https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
  6. Матиевская Н.В., Кашевник Т.И., Казыро Л.М. Гендерные и возрастные особенности течения ВИЧ-инфекции. Клиническая инфектология и паразитология 2018; 7(4): 498-507.
  7. Gantner P., Cuzin L., Allavena C., Cabie A., Pugliese P., Valantin M-A. et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017; 18: 704-708. doi: 10.1111/hiv.12506
  8. Llibre J.M., Hung C.C., Brinson C., Castelli F., Girard P.-M., Kahl L.P. et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391: 839-49. doi: 10.1016/S0140-6736(17)33095-7
  9. Taiwo B.O., Marconi V.C., Berzins B., Moser C.B., Nyaku A.N., Fichtenbaum C.J., Benson. et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin. Infect. Dis. 2018; 66: 1794-7. doi: 10.1093/cid/cix 1131
  10. Cahn P., Madero J.S., Arribas J.R., Antinori A., Ortiz R., Clarke A.E. et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovirdisoproxilfumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393: 143-55. doi: 10.1016/S0140-6736(18)32462-0
  11. US Department of Health and Human Services. Guidelines for the use of anti-retroviral agents in adults and adolescents living with HIV. https://aidsinfo.nih.gov/guidelines
  12. European AIDS Clinical Society. EACS treatment guidelines 10.0. http://www.eacsociety.org/
  13. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2019; 9(4, приложение). http://www.hivrussia.info/metodicheskie-rekomendatsii-i-protokoly/
  14. Li L., He H., Lan Y., Chen J., Zhong H., Nie J. et al. Dual Therapy with Lopinavir/Ritonavir plus Lamivudine could be a Viable Alternative for Antiretroviral-Therapy-Naive Adults with HIV-1 Infection Regardless of HIV Viral Load or Subgenotype in Resource-Limited Settings: A Randomised, Open-Label and Non-Inferiority Study from China. Indian J. Med. Microbiol. 2018; 36(4): 513-16. doi: 10.4103/ijmm. IJMM_18_172
  15. Cahn P., Andrade-Villanueva J., Arribas J.R., Gatell J.M., Lama J.R., Norton M. et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect. Dis. 2014; 14(7): 572-80. DOI: 10.1016/ S1473-3099(14)70736-4
  16. Матиевская Н.В. Антиретровирусная терапия ВИЧ-инфекции: перспективы упрощения схем. ВИЧинфекция и иммуносупрессии 2017; 9(2): 27-35. doi.org/10.22328/2077-9828-2017-9-2-27-35

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies